On January 21, 2021 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) – a novel class of drug derived from the microbiome, reported its participation in the Microbiome Movement Drug Development Summit – Europe, including the Plenary Session, Microbiome Leaders Industry Review Panel (Press release, 4d Pharma, JAN 21, 2021, View Source [SID1234574182]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Plenary Session: European Microbiome Leaders Panel Discussion on Thursday, January 28, 2021 at 8:00am GMT (3:00am ET) with Chief Scientific Officer, Dr. Alex Stevenson, Ph.D.
Clinical Trial Design and Evaluating PK/PD Session: MicroRx and Single Strain Live Biotherapeutics: Proof of Concept Clinical Data and Future Considerations on Thursday, January 28, 2021 at 11:30pm GMT (6:30am ET) with Research Director, Dr. Imke Mulder